VTEU Principal Investigators
Angela R. Branche, MD
University of Rochester Vaccine and Treatment Evaluation Unit
angela_branche@urmc.rochester.edu
More about Angela R. BrancheC. Buddy Creech, MD, MPH
Vanderbilt Vaccine and Treatment Evaluation Unit
More about C. Buddy CreechAnn R. Falsey, MD
University of Rochester Vaccine and Treatment Evaluation Unit
Ann.Falsey@rochesterregional.org
More about Ann R. FalseyRobert W. Frenck, Jr., MD
Cincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units
Dr. Frenck's research interests include therapeutic and vaccine clinical trials with special interest in enteric diseases and human challenge infection models. After completing a 25-year career in the Navy, Dr. Frenck joined the UCLA Center for Vaccine Research in 2004 and served until 2006 as director of the center and a professor of pediatrics at UCLA School of Medicine. Dr. Frenck has been active in the American Academy of Pediatrics and is the incoming Chair for the Section on Infectious Diseases (SOID) as well as serving in the Red Book Committee. He is an acknowledged authority in infectious diseases and has authored over 150 articles and book chapters on various aspects of this subject.
Daniel Hoft, MD, PhD
Vaccine and Treatment Evaluation Unit at Saint Louis University
More about Daniel HoftLisa Jackson, MD, MPH
Kaiser Washington Vaccine and Treatment Evaluation Unit
Dr. Jackson is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991. She has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.
Karen Kotloff, MD
University of Maryland School of Medicine Center for Vaccine Development and Global Health
kkotloff@medicine.umaryland.edu
Dr. Kotloff's research focuses on the epidemiology of infectious diseases and their prevention with the use of vaccines in both the U.S. and developing countries. She has led numerous clinical trials to evaluate vaccines against a wide range of infections, including group A streptococcus, Shigella, and influenza. She participates in numerous international advisory committees for the Bill & Melinda Gates Foundation and the World Health Organization.
R. Scott McClelland, MD, MPH
University of Washington Vaccine and Treatment Evaluation Unit
Dr. McClelland is a board certified physician at the Infectious Disease & Travel Medicine Clinic at Harborview and a UW professor of Medicine, Epidemiology and Global Health. He earned his MD and MPH at the UW. His research focuses on prevention and treatment of HIV and sexually transmitted infections, particularly in high-risk African women.
Mark J. Mulligan, MD
NYU Grossman School of Medicine Vaccine Center
Dr. Mulligan is an international leader in infectious disease research programs for more than three decades, and his pioneering work has profoundly advanced the field. He is the director of the Division of Infectious Diseases and Immunology and the inaugural director of the Vaccine Center at NYU Langone Health.
Anna Wald, MD, MPH
University of Washington Vaccine and Treatment Evaluation Unit
Dr. Wald's current research centers on the epidemiology and natural history of chronic viral infections in immunocompetent and immunocompromised hosts. She is also working on clinical trials of antiviral therapeutics and prophylactic and therapeutic vaccines for viral pathogens. Other ongoing studies address the interaction between sexually transmitted infections and microbiome. Dr. Wald emphasizes that many chronic conditions, including chronic viral infections, can only be managed with the active participation of person affected by the condition. She is a fellow of American College of Physician and Infectious Diseases Society of America. Her clinical and research interests include infectious diseases, clinical virology, sexually transmitted infections, infections in immunocompromised persons, epidemiology and vaccines for herpes virus infections.